Eight Sleep raises $100M, targets FDA approval for sleep apnea and menopause, and eyes China expansion
Aug 19, 2025 with Matteo Franceschetti
Key Points
- Eight Sleep raises $100 million to reach $250 million total funding, positioning China as a single lever that could double the business and adding HSG as a new investor focused on Asian expansion.
- The company is filing with the FDA for sleep apnea and menopause-related hot flashes, betting that medical device classification will unlock insurance reimbursability and transform unit economics.
- Eight Sleep is building a sleep agent powered by AI that adjusts bed conditions dynamically and a longevity platform projecting disease risk over 10 to 20 years, pivoting from sleep product toward health platform.
Summary
Eight Sleep has closed a $100 million funding round, bringing total capital raised to $250 million. The company describes itself as free cash flow positive for the full current year and for most of the past ten quarters, framing the raise as opportunistic rather than necessary. Returning investors include Valor Equity Partners, led by Antonio Gracias, and new entrant HSG, which was brought in specifically to accelerate expansion into China and broader Asia.
Matteo Franceschetti, Eight Sleep's CEO, identifies China as the single largest near-term growth lever, claiming it could double the business on its own. The company currently operates in 30 countries. The hardware-software integration is positioned as the primary moat against local Chinese competitors, with the argument that thermal regulation at scale is technically far harder to replicate than it appears.
Medical and FDA Strategy
A significant portion of the new capital is earmarked for FDA filings across at least two indications: sleep apnea and menopause-related hot flashes. The strategic logic is insurance reimbursability. If the Pod hardware qualifies as a medical device, it opens a pathway for partial or full insurance coverage, materially changing the addressable market and unit economics. Eight Sleep has already launched a "hot flash mode" allowing users to trigger immediate bed cooling with a tap, and Franceschetti says thousands of women are already using it nightly.
AI and Longevity Positioning
The third capital allocation pillar is AI. Eight Sleep is developing what it calls a sleep agent, described as a PhD-level sleep coach that simulates an upcoming night using historical sleep data and real-time health inputs via Apple Health, then adjusts bed conditions dynamically as the user falls asleep. A second initiative, internally called longevity twins, generates thousands of individual health simulations per user, projecting disease likelihood over a 10 to 20 year horizon. The framing is an explicit pivot from sleep as a product category toward longevity as a platform play.
New hardware products are also confirmed for next year, though no further detail was provided.